Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: Rationale for consolidation docetaxel therapy

David R Gandara, Eric Vallières, Laurie E. Gaspar, Karen Kelly, Kathy S. Albain, Roy S. Herbst, Primo N Lara, Philip Mack, Paul H. Gumerlock, John J. Crowley

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Currently, there is no accepted standard of care for locally advanced and surgically unresectable non-small-cell lung cancer. Typically, treatment for patients with good performance status consists of a combination of chemotherapy and thoracic radiation therapy (RT), but the Integration of these modalities and the respective dose schedules vary considerably. Herein, we review the rationale for a treatment paradigm employing consolidation docetaxel therapy after concurrent chemotherapy/RT and the results of recent clinical trials using this approach.

Original languageEnglish (US)
JournalClinical Lung Cancer
Volume7
Issue numberSUPPL. 3
DOIs
StatePublished - Dec 2005

Keywords

  • Gefitinib
  • Stage III disease
  • Surgery
  • Taxanes

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: Rationale for consolidation docetaxel therapy'. Together they form a unique fingerprint.

  • Cite this